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Activity of distinct growth factor receptor
network components in breast tumors
uncovers two biologically relevant subtypes
Mumtahena Rahman1,2†, Shelley M. MacNeil1,3†, David F. Jenkins4†, Gajendra Shrestha1, Sydney R. Wyatt1,
Jasmine A. McQuerry1,3, Stephen R. Piccolo2,6, Laura M. Heiser5, Joe W. Gray5, W. Evan Johnson3,4
and Andrea H. Bild1,2,3*

Abstract
Background: The growth factor receptor network (GFRN) plays a significant role in driving key oncogenic
processes. However, assessment of global GFRN activity is challenging due to complex crosstalk among GFRN
components, or pathways, and the inability to study complex signaling networks in patient tumors. Here,
pathway-specific genomic signatures were used to interrogate GFRN activity in breast tumors and the
consequent phenotypic impact of GRFN activity patterns.
Methods: Novel pathway signatures were generated in human primary mammary epithelial cells by overexpressing
key genes from GFRN pathways (HER2, IGF1R, AKT1, EGFR, KRAS (G12V), RAF1, BAD). The pathway analysis toolkit
Adaptive Signature Selection and InteGratioN (ASSIGN) was used to estimate pathway activity for GFRN components in
1119 breast tumors from The Cancer Genome Atlas (TCGA) and across 55 breast cancer cell lines from the Integrative
Cancer Biology Program (ICBP43). These signatures were investigated for their relationship to pro- and anti-apoptotic
protein expression and drug response in breast cancer cell lines.
Results: Application of these signatures to breast tumor gene expression data identified two novel discrete
phenotypes characterized by concordant, aberrant activation of either the HER2, IGF1R, and AKT pathways
(“the survival phenotype”) or the EGFR, KRAS (G12V), RAF1, and BAD pathways (“the growth phenotype”). These
phenotypes described a significant amount of the variability in the total expression data across breast cancer
tumors and characterized distinctive patterns in apoptosis evasion and drug response. The growth phenotype
expressed lower levels of BIM and higher levels of MCL-1 proteins. Further, the growth phenotype was more
sensitive to common chemotherapies and targeted therapies directed at EGFR and MEK. Alternatively, the
survival phenotype was more sensitive to drugs inhibiting HER2, PI3K, AKT, and mTOR, but more resistant to
chemotherapies.
Conclusions: Gene expression profiling revealed a bifurcation pattern in GFRN activity represented by two
discrete phenotypes. These phenotypes correlate to unique mechanisms of apoptosis and drug response and
have the potential of pinpointing targetable aberration(s) for more effective breast cancer treatments.
Keywords: Breast cancer, Gene expression signatures, Cancer phenotypes, Growth factor receptor network,
Genomics, Targeted therapy
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Background
Breast cancer remains one of the leading causes of
cancer-related death in women [1]. It is well established
that growth factor receptors and their downstream signaling pathways, contribute to breast cancer proliferation,
survival, and metastasis [2, 3]. Molecular aberrations can
occur in various growth factor receptor network (GFRN)
members and have been described in breast cancer [4–6].
These findings have paved the way for GFRN-targeted
treatments which are currently approved for use and being evaluated in various stages of clinical development
and in clinical trials [7, 8]. Although these treatments do
hold promise, relatively few data are available on the cooperativity and diversity of complicated GFRN signaling in
actual breast tumors. Additionally, assessing GFRN activity in patient tumors is extremely challenging due to the
lack of methods capable of measuring signaling events in
tumors. Drug selection is often guided by expression of
protein biomarkers, and drug resistance often develops
due to compensation by interacting pathways within the
GFRN [9, 10]. Therefore, there is a strong need to develop
better methods for measuring and understanding GFRN
signaling events in breast tumors in order to deliver
the most effective treatment regimens and combat
drug resistance [2, 9, 11].
Growth factor receptors, such as epidermal growth
factor receptor 1 (EGFR), human epidermal growth factor receptor 2 (HER2), and insulin-like growth factor 1
receptor (IGF1R), are key regulatory nodes of the GFRN
and are often aberrantly activated across breast cancer
subtypes [6, 12, 13]. Approximately 15–30% of breast
cancer patients are diagnosed with HER2-positive breast
cancer, which is characterized by amplification of HER2
[12]. EGFR amplifications occur in 25% of all triplenegative breast cancer (TNBC) patients and are often
associated with poor outcomes [6, 8, 14]. High IGF1R
activity occurs in up to 50% of breast tumors and is
seen across all breast cancer subtypes [13]. These receptors can activate downstream oncogenic growth cascades such as the phosphoinositide 3-kinase (PI3K) and
mitogen-activated protein kinase (MAPK) pathways,
forming a complex, interconnected, and dynamic signaling network [2, 8]. Activation of PI3K by growth factor receptors triggers the PI3K/AKT/mammalian target
of rapamycin (mTOR) pathway, leading to cell proliferation, metabolic changes, and cell survival [15–17]. In
the MAPK pathway, following growth factor receptor
activation, RAS becomes activated followed by activation of RAF1, MEK, and ERK, leading to transcriptional
changes that impact cellular proliferation, motility, and
evasion of apoptosis [6, 8, 18, 19]. Both the PI3K and
MAPK pathways contribute to tumor progression by
disrupting the balance of pro- and anti-apoptotic proteins of the BCL-2 protein family in the mitochondrial
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(also known as intrinsic) pathway of apoptosis [20, 21].
Particular GFRN members can upregulate anti-apoptotic
proteins such as BCL-2, BCL-XL, and MCL-1 and downregulate pro-apoptotic proteins such as BAD, BAX, and
BIM, all of which contribute to apoptosis evasion and resistance to cancer treatments in patients [22–29]. ERBB
receptor tyrosine kinases, such as EGFR and HER2, have
a great deal of overlap in the downstream pathways they
activate; however, individual ERBB receptors have the
capability to preferentially bind particular downstream
signaling molecules [30, 31]. Furthermore, preclinical
studies have shown that EGFR− and HER2-driven cancers show differential response to targeted therapies.
EGFR mutant cancers are less responsive to single-agent
PI3K/AKT inhibitors in comparison to HER2-amplified
cancers and require the inhibition of both the PI3K and
MEK pathways [32]. These suggest that ERBB proteins
can couple to distinct signaling pathways and invoke
non-redundant physiological effects, which warrants for
specificity for the different GFRN components. Therefore, an accurate assessment of global GFRN activity is
pivotal for selecting targeted treatment strategies that
consider the diversity of growth and cell survival mechanisms in breast cancer patients.
Despite advances in the cellular and molecular
characterization of breast cancer, effective personalized
breast cancer treatment remains elusive. Immunohistochemical and gene expression profiling-defined breast
cancer molecular classification has advanced our understanding of breast cancer prognosis, treatment, and improved survival. Currently, breast cancers are stratified
into different clinical subtypes in order to determine
specific treatments, and several breast cancer subtyping
approaches are currently available. For example, fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC) techniques are often used to determine
clinical subtypes based on common receptor protein alterations such as estrogen (ER), progesterone (PR), and
HER2 receptor amplification [7, 33]. Additionally, Ki-67
(proliferation marker), CK 5/6 (cytokeratin marker), EGFR,
androgen receptor (AR), and p53 (apoptosis marker) are
used as biomarkers to further classify breast cancer using
IHC methods. Although helpful, IHC methods are often
subjected to bias due to tissue handling, fixation, antibody
sources, and need for physical evaluation by pathologists
[34, 35]. More recently, Perou [14, 36] and Sørlie et al. [37]
proposed five “intrinsic subtypes” that have shown utility
in guiding therapy by leveraging gene expression data,
differences in clinical outcomes, and responses to neoadjuvant chemotherapy [7, 38]. Further, evaluation of gene expression has led to the proposition of several additional
subtypes, including claudin-low, molecular apocrine, and a
novel luminal-like subtype [39–44]. While molecular
subtypes continue to emerge, routine use of such subtypes
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in clinical settings is not sensitive and specific due to some
critical limitations. For example, tumors of the same
clinical or intrinsic subtype can show differences in
growth, survival, and response to therapies [45], and clinical and intrinsic subtypes are sometimes discrepant [46].
Approximately one-third of HER2+ tumors are not classified as the HER2-enriched intrinsic subtype and up to 25%
of clinically characterized ER+ tumors are not classified as
the luminal intrinsic subtype [36]. While IHC methods are
single protein based, intrinsic subtypes are fundamentally
empirical and do not focus on distinct biological properties. Thus, both IHC and intrinsic subtypes fail to recapitulate the biological heterogeneity within each subtype [47].
Recent studies highlight the discordance between the
IHC and intrinsic subtypes, which calls for additional
work [47, 48]. To address these challenges, pathwaylevel subtyping may provide complementary information
for determining therapeutic targets. For example, identification of specific aberrant pathways within the triple
negative and basal-like subtypes may help to explain
additional heterogeneity and better target these subtypes
pharmacologically [49]. Here, breast cancer inter-tumor
heterogeneity was explored in terms of GFRN activity
for its well-known role in growth, evasion of apoptosis,
and drug response.
While biochemical measurement of pathway activity
is challenging in human tumors due to limited tissue
availability and instability of specific proteins, patterns
of activity across multiple genes—or gene expression
signatures—can be used as surrogates for pathway activation in tumors and to model biological phenotypes
[50–54]. Pathway activation has been used to predict drug
response to targeted therapies in cell lines [52, 54, 55], but
to the best of our knowledge, this is the first study which
measures activity of seven GFRN members concurrently
at the pathway level in patient samples. In this study, 1119
breast tumors were profiled for GFRN activity across The
Cancer Genome Atlas (TCGA) and across 55 breast cancer cell lines from the Integrative Cancer Biology Program
(ICBP43) [56, 57] (Fig. 1). Pathway activity was estimated
in samples using novel GFRN gene expression signatures
for the HER2, IGF1R, AKT, EGFR, KRAS (G12V mutation), RAF1, and BAD pathways. These GFRN signatures
were generated by performing sequencing on RNA collected from primary human mammary epithelial cells
(HMECs) overexpressing HER2, IGF1R, AKT1, EGFR,
KRAS (G12V), RAF1, or BAD for 18–36 h. These signatures capture early transcriptional events, which occur
shortly after oncogene activation, and represent the
transcriptional profile of pathway activation, and not of
a transformed cell.
Using the pathway analysis toolkit Adaptive Signature
Selection and InteGratioN (ASSIGN), the signatures
were projected onto each breast cancer data set and
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uncovered two discrete patterns of GFRN activity [58].
One pattern was characterized by concurrent activation
of the HER2, IGF1R, and AKT pathways, and another
was characterized by concurrent activation of the EGFR,
KRAS, RAF1, and BAD pathways. Typically, when one
set of pathways was active, the other set was inactive,
indicating that each sample tends to have a dominant
GFRN phenotype. Pathways activation of HER2, IGF1R,
and AKT was nicknamed the “survival phenotype” and
activation of EGFR, KRAS, RAF1, and BAD as the
“growth phenotype”. These names were chosen for simplicity and based on the known role of AKT signaling
in cancer cell survival and the known role of EGFR/
RAS signaling in cellular growth [59, 60]. Importantly,
genomic pathway activity corresponded to apoptotic
phenotypes. The growth phenotype showed upregulation of anti-apoptotic protein MCL-1 and downregulation of pro-apoptotic protein BIM as a mechanism of
escaping apoptosis. Additional subgroups were also
identified within each phenotype, including HER2 high
and HER2 low activity groups within the survival
phenotype and BAD high and BAD low activity groups
within the growth phenotype. These discrete subgroups
displayed differences in response to targeted therapies
and chemotherapies. Therefore, these phenotypes can
serve as surrogates for GFRN activity that capture
significant variability in the gene expression data, differentiate survival mechanisms, and correlate to drug
response significantly. A major component of the heterogeneity found across tumor expression data was
contributed by GFRN signaling and was independent of
ER, PR, and HER2 status compared to intrinsic subtypes. Additionally, a unique aspect is that GFRN activity explained the data in a biologically meaningful way.
For example, while intrinsic subtyping approaches are
based on empirical patterns of gene expression and do
not necessarily represent a biological process, the subgrouping approach represents aberrant activity in
specific GFRN pathway signaling. Therefore, pathwaybased phenotypes and subgroups have the potential to
complement existing methods and identify biologically
and clinically relevant patterns in tumors. Taken together, pathway signatures not only aid in assessing
general pathway activity patterns in a biologically relevant way, but also show promise to select better treatment targets for breast cancer patients.

Methods
Overexpression of genes of interest in human mammary
epithelial cells

In order to create gene expression signatures representative of pathway activation, GFRN oncogenes were overexpressed in HMECs. HMECs from a non-cancer-related
breast reduction surgery performed at the University of
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Fig. 1 High-level overview for probing growth factor receptor networks in breast cancer. a Overexpression of growth factor receptor network
(GFRN) genes in human mammary epithelial cells (HMECs): AKT, BAD, EGFR, HER2, IGF1R, RAF1, and KRAS (G12V). b Generation of RNA-sequencing
data from HMECs overexpressing GFRN genes and signature generation using ASSIGN. c Determination of GFRN pathways activation across TCGA
breast tumors and ICBP breast cancer cell lines and identification of novel phenotypes based on GFRN activity. d Linking novel phenotypes to
survival and drug response mechanisms in biochemical and drug response assay

Utah were isolated and cultured according to previously
published protocols [61]. Cells were grown in serum-free
mammary epithelial basal medium (MEBM) plus the
addition of a “bullet kit” (Lonza) and supplemented with
5 mg/ml transferrin and 10−5 M isoproterenol at 5% CO2.
Cells were brought to quiescence by growth in low serum
conditions (0.25% MEBM + bullet kit, no EGF) for 36 h.
Cells were infected with recombinant adenovirus (at 500
MOI) expressing either human oncogenes AKT1, IGF1R,

BAD, HER2, KRAS (G12V), and RAF1 or GFP control
(Additional file 1: Figure S1). Cells were incubated with
virus for 18 h except for KRAS (G12V), which was incubated for 36 h. The adenoviral expression systems invoke
transient gene expression changes, which allow us to
capture the early transcriptional events of each oncogene,
as opposed to the transcriptional profile of a transformed
cell. Recombinant adenoviruses were amplified and concentrations were determined using previously published
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protocols [62]. All viruses were obtained from Vector
Biolabs, except RAF1 (Cell Biolabs) and EGFR (gift
from Duke University).
Western blot analysis for expression of growth factor
proteins in HMECs and apoptotic proteins in breast
cancer cell lines

Proteins from HMECs and following cell lines were
extracted: HCC3153, HCC1395, ZR75B, HCC1569,
HCC2218, SKBR3, LY2, SUM52PE, ZR7530, MDAMB361,
AU565, BT474, BT483, CAMA1, HCC1419, HCC1428,
MCF7, MDAMB175, T47D, ZR751, HCC1954, JIMT1,
BT549, HCC1143, HCC1806, HCC1937, HCC38, HCC70,
HS578T, and MDAMB213 (Additional file 2: Sheet 1).
To collect protein, cells were washed with PBS, scraped on
ice into PBS, pelleted by centrifugation, lysed in lysis buffer
for 15 minutes (50 mM Tris (pH 8.0), 140 mM NaCl,
5 mM EDTA, 1% TritionX-100, 0.1% SDS, protease
cocktail (Sigma), phosphatase inhibitors cocktails 2 and 3
(Sigma), and centrifuged at 13,000 × g for 15 minutes.
Protein quantification of lysates was determined using a
BCA assay (Pierce). Electrophoresis was performed on a
8–12% Tris-HCl polyacrylamide gel (BioRad) for HMEC
Western blots and 18% Criterion TGX Tris/Glycine gels
(BioRad) for apoptotic protein western blots. Proteins were
then transferred to a PVDF membrane using the iBlot® 2
Dry Blotting System (Thermo Fisher Scientific). Membranes were blocked for 1 h with SuperBlock™ (Thermo
Fisher Scientific) and probed with the following primary
antibodies: AKT (#9272), pAKT (#13038), BAD (#9292),
EGFR (#4267), pEGFR (#2234), HER2 (#2165), pHER2
(#2244), IGF1R (#3027), pIGF1R (#3021), KRAS (sc-30),
pMEK (#9154), p-cRAF (#9427), GAPDH (#5174), and
β-tubulin (#2146). Of note, pAKT ran higher than expected due to AKT myristoylation. Breast cancer cell line
lysates were probed with the following: MCL-1 (#5453),
BIM (#2933), and B-actin (#3700). All antibodies were
obtained from Cell Signaling Technology, besides KRAS,
which was obtained from Santa Cruz.
Dose response assay

Cell lines were plated at 2000 cells per well in 384 well
plates for 24 h at 37 °C. Detailed information on the cell
lines and their growth conditions is provided in Additional
file 2: Sheet 1. All cell lines were obtained from American
Type Culture Collection (ATCC). Drugs were diluted to
six doses in media containing 5% FBS (Gibco/Life technologies) and 1% anti–anti (Gibco/Life technologies).
Erlotinib, trametinib, UMI-77, obatoclax, doxorubicin,
and neratinib were purchased from Selleckchem, and
bafilomycin and AKT1/2 inhibitor were from SigmaAldrich. Drugs were dissolved in 100% DMSO and
stored at −80 °C. Detailed information on drug doses is
provided in Additional file 2: Sheet 2. Cell viability and
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growth was measured using CellTiter-Glo (Promega)
72 h post-treatment. All treatment doses were performed in four replicates. The Drug Discovery Core
Facility, a part of the Health Sciences Cores at the
University of Utah, performed the dose response assay.
EC50s (concentration of each drug that provides half of
the maximum response) were determined and converted
to drug sensitivity values defined as the negative log of
the EC50s (−logEC50) (Additional file 2: Sheet 3). EC50
values were calculated from dose response data by
plotting in GraphPad Prism 4 and using the equation
Y = 1/(1 + 10ˆ((logEC50 − X) × HillSlope)) with a variable
slope (Ymin = 0 and Ymax = 1).
RNA preparation and RNA sequencing

After transfection with adenovirus and Western blot validation, cells were pelleted, washed in PBS, and stored in
RNAlater (Ambion). Cells were then DNase treated, and
RNA was extracted using the RNeasy kit (Qiagen). RNA
replicates were generated for each overexpressed gene:
six each for AKT, BAD, IGF1R, and RAF1; five for HER2;
and 12 for GFP control (Gene Expression Omnibus (GEO)
accession GSE83083). Additionally, 9 replicates of each of
KRAS and GFP control were generated (GEO accession
GSE83083). The EGFR signature and its corresponding
GFP control were previously generated with six replicates
of each (GEO accession GSE59765). RNA concentration
was determined with a Nanodrop (ND-1000). cDNA libraries were prepared from extracted RNA using the Illumina Stranded TruSeq protocol (Illumina). cDNA libraries
were sequenced at Oregon Health and Sciences University
using the Illumina HiSeq 2000 sequencing platform with
six samples per lane. Single-end reads of 101 base pairs
were generated.
Gene expression data processing, normalization, and
datasets

The Rsubread R package (version 1.14.2) was used to
align and summarize RNA-seq reads to the UCSC hg19
reference genome and annotations [63, 64]. All RNA-seq
data in this study, including HMEC overexpression
data (GSE83083, GSE59765), TCGA breast cancer data
(GSE62944), and ICBP breast cancer RNA-Seq dataset
(GSE48213), were processed and normalized using a
pipeline that can be found at https://github.com/srp33/
TCGA_RNASeq_Clinical [60, 65].
Generation of gene expression signatures

Adaptive Signature Selection and InteGratioN (ASSIGN;
version 1.9.1), a semi-supervised pathway profiling toolkit, was used to generate gene expression signatures. A
formal definition of the ASSIGN model and software
implementation was reported previously [58]. RNA-Seq
data from HMECs overexpressing GFP control were
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compared to HMECs overexpressing AKT1, IGF1R, BAD,
HER2, KRAS (G12V), RAF1, and EGFR. ASSIGN uses a
Bayesian variable approach to select genes with the highest weights and signal strengths, indicating differential
expression. These genes represent oncogenic signatures
(Additional file 1: Figure S2).
Gene set enrichment analysis on RNA-Seq signatures

The R package Gene Set Variation Analysis for microarray and RNA-Seq data (GSVA; version 1.22.0), a nonparametric, unsupervised method for estimating variation of gene set enrichments in gene expression data,
was used to perform this gene set enrichment analysis
[66]. GSVA was downloaded from Bioconductor (3.4).
RNA-Seq data from HMECs overexpressing GFP (control),
AKT1, IGF1R, BAD, HER2, KRAS(G12V), RAF1, and
EGFR was used as input for the GSVA algorithm. The
following gene sets were used and downloaded from the
Molecular Signatures Database (http://software.broadins
titute.org/gsea/downloads.jsp) [67]; 1320 gene sets from
the C2: canonical pathways collection (c2.cp.v5.2.symbols.gmt) and 50 gene sets from the hallmarks collection
(h.all.v5.2.symbols.gmt). The following GSVA parameters
were used: minimum gene set size = 10, maximum gene
set size = 500, verbose = TRUE, rnaseq = TRUE, and
method = “ssgsea”. GSVA returns a matrix containing
enrichment scores for each sample and gene. The R
package limma (version 3.30.2) [68] was used to perform
a differential expression analysis between each overexpressed gene sample and its respective GFP control
sample. The full results from the gene set enrichment
analysis can be found in Additional file 3.
Batch adjustment and estimation of pathway activity in
ICBP and TCGA BRCA patient samples

HMEC oncogenic signatures (training data) were applied
to 55 ICBP breast cancer cells and 1119 TCGA breast
cancer patient gene expression datasets (test data) to estimate pathway activation status. To avoid confounding
batch effects within and between the training and test
data, the data were adjusted for batch effects. First, in
order to visualize batch effects in the data a principal
component analysis (PCA) was performed on the training (HMEC overexpression RNA-Seq) data. The training
data were sequenced separately in three batches, and significant batch effects were observed. Batch effects were
adjusted using the ComBat function from the R package
sva (version 3.21.1) [65, 69]. ComBat was run using the
reference-batch option, which adjusts the data to match
an indicated batch. The sequencing batch containing
AKT1, IGF1R, BAD, HER2, and RAF1 was selected as
the reference batch. A model-matrix indicating which
pathway was associated with each training replicate was
also included. After the first batch adjustment, PCA was
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performed on the adjusted training data and the test
data (ICBP breast cancer cell lines or TCGA breast tumors). Significant batch effects were identified between
the training and test data and performed a second round
of ComBat adjustment, using the training data as the
reference batch. After the second batch adjustment,
PCA was performed to confirm the resolution of the
batch effect. Additionally, background baseline gene
expression differences were adjusted between oncogenic
signatures and test samples (ICBP cell lines and TCGA
patient data) using ASSIGN’s adaptive background
parameter. The variation in magnitude and direction of
signature-relevant gene expression between oncogenic
signature training samples and test samples was adjusted using ASSIGN’s adaptive signature parameter.
The model specification options for all analyses are
listed in Additional file 1: Table S1. Default ASSIGN
settings were used for all other parameters.
Optimization of single-pathway estimates in ICBP cell line
and TCGA BRCA patient data

To determine the optimum number of genes for each
oncogenic signature, signatures with gene list lengths
from 25 to 500 genes, in 25 gene increments, were
generated using ASSIGN’s single pathway settings. By
default, ASSIGN chooses gene lists that contain an equal
number of genes that have increased or decreased expression with pathway activation. ASSIGN also allows a
specific gene to be anchored in the signature, making
sure that the gene is always included in the signature,
even if it is not chosen during gene selection or if it is
removed from the signature after Monte Carlo simulation. Anchor genes were chosen based on the oncogene
overexpressed in each signature. Pathway predictions
generated by ASSIGN are represented as values from
zero to one. Values of zero represent no pathway activity
and values of one represent high pathway activity. For all
the signatures that passed internal leave-one-out crossvalidation, pathway estimates were included for further
validation in proteomics, mutation, and gene expression.
To determine optimal signature gene list lengths and
evaluate the robustness of the generated signatures,
pathway activation estimates from ICBP and TCGA
were correlated with proteins that reflect downstream
pathway activation from corresponding ICBP and TCGA
RPPA data as a measurement of protein quantity [70, 71].
Significant correlations were found between pathway activation estimates for all GFRN signatures and appropriate
downstream pathway proteins [13, 72–74] (Additional
file 1: Table S1). Mutation-based analysis was performed
using t-tests between patient groups based on mutation
status in oncogenic proteins. For example, TCGA mutation data were analyzed and higher AKT activation and
lower BAD activation estimates were found in patients
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with PI3KCA mutations (Additional file 1: Figures S3a,
b) and higher HER2 pathway activation estimates
were found in HER2-positive tumors (Additional file 1:
Figure S3c). In gene expression data, higher pathway
activity for AKT, EGFR, IGF1R, and RAF1 in TCGA
samples classified as “high” expressing using percentiles
from TCGA RNA-Seq dataset for their respective genes
AKT1, EGFR, IGF1R, and RAF1 were found (Additional
file 1: Figure S3d–g). Samples with 90th percentile or
higher expression were considered “high”, 10th percentile or lower “low”, and 10th to 90th percentile “intermediate” expressing samples for AKT1, EGFR, and
RAF1. For IGF1R validation, samples with 80th percentile or higher IGF1R expression were considered
“high”, 20th percentile or lower “low”, and 20th to 80th
percentile “intermediate” expressing samples. Finally,
pairwise Spearman correlation values and calculated p
values between pathway predictions and corresponding
TCGA reverse phase protein array (RPPA) data were
used to determine which gene numbers gave the best
correlations. The HER2 and AKT signatures performed
better with fewer genes. Therefore, 5, 10, 15, and 20
gene signatures for HER2 and AKT were generated.
Significant correlations were seen between pathway estimates and RPPA protein scores. For example, AKT
pathway activation estimates were significantly correlated with AKT, PDK1, and phosphorylated-PDK1 protein levels in both ICBP and TCGA (p values <0.0001)
samples. Due to the lack of proteins available to validate the BAD signature, negative correlations between
BAD pathway estimates and AKT protein based on the
knowledge that activation of AKT leads to BAD inhibition were used [23]. The optimized gene list was the
list that gave the best average correlation in the expected direction for the RPPA data correlated with each
pathway in TCGA data and was significant both in
ICBP and TCGA data, with an ICBP correlation of at least
0.3 and a maximum gene list length of 300 genes.
Additional file 4 includes a gene list of optimum gene
numbers determined for each signature. Additional file 5
contains scaled ASSIGN pathway activity predictions for
each of the seven optimized pathways in TCGA and ICBP.
Software implementation of pathway activity prediction
with generated signatures

The signatures presented here have been included in the
latest version of the ASSIGN package (version 1.11.3) so
that pathway activity prediction can be easily performed
on other datasets. Because the gene list length can affect
the results of ASSIGN analysis, the signatures can be
used in their original form, or the gene list lengths can
be optimized based on maximizing correlations between
ASSIGN activity predictions and a set of variables, such
as RPPA data.
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Determination of growth factor phenotypes in ICBP
and TCGA

Cell lines from ICBP, patient tumors from TCGA, and
breast cancer cell lines for in vitro experiments were
classified as either the survival or growth phenotype by
calculating the mean of scaled pathway activation values
for HER, IGF1R, and AKT for the survival phenotype
and the mean of scaled pathway activation values for
BAD, EGFR, KRAS, and RAF1 for the growth phenotype. Each sample was classified as either survival or
growth phenotype based on which phenotype had the
highest mean (Additional file 5).
Identification of additional drug response heterogeneity
within growth factor phenotypes

To classify samples into subgroups within the growth
factor phenotypes that corresponded to high and low
HER2 activity within the survival phenotype and high
and low BAD activity within the growth phenotype, the
R function kmeans was used to perform k-means clustering on the scaled pathway activity data for AKT,
HER2, BAD, and EGFR pathways with four means and
100 random starts. Additional file 5 contains sample
classifications for the ICBP and TCGA data. After classifying samples, t-tests were performed using the R function t.test on known HER2/AKT/PI3k/mTOR targeting
drugs and EGFR/MEK targeting drugs from the drug
response assay described above between the cell lines
identified as AKT/HER2 high and AKT/HER2 low, and
between the cell lines identified as EGFR/BAD high and
EGFR/BAD low. P values were corrected using a FDR
correction and identified drugs that showed a significantly different drug response among the growth factor
subgroups. When determining how growth phenotypes
and ER, PR, and HER2 status performed in assessing
drug response, mean drug response across all available
cell lines as the cutoff were used. Cell line drug sensitivity value above this cutoff was considered as “sensitive”
and otherwise “resistant”.
Statistical analyses

The prcomp function from the stats R package was used
to compute the principal components in TCGA breast
cancer patient RNA-Seq data. The Spearman rank-based
pairwise correlation method was used for all principal
component-based correlations, pathway predictions, and
protein correlations. The cor.test function from the stats
R package was used to calculate p values for each correlation [75–77]. Student’s t-tests were used to find the
differences in principal component values based on
IHC-based subtypes and mutation status within GFRN
phenotypes; pathway activity based on mutation status
and drug; sensitivity differences based on pathway activity,
and gene expression boxplots. The heatmap.2 function
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from the ggplots R package and the Heatmap function
from the ComplexHeatmap R package were used for
generating pathway activity and pathway activity–drug
response correlation heatmaps [78, 79]. The lm function
from the stats R package was used to model principal
component values in TCGA using clinical subtypes,
intrinsic subtypes, and GFRN subgroups to determine R2
values. Models were compared using the anova function
from the stats package to determine significance of adding
additional features to the models. All analyses were
conducted in R and the code is available at https://github.
com/mumtahena/GFRN_signatures [80].

Results
Two dominant phenotypes in breast cancer patients and
cell lines

Gene expression signatures were developed and validated for the following GFRN pathways: AKT, BAD,
EGFR, HER2, IGF1R, KRAS (G12V mutation), and
RAF1. Signatures were generated in normal human
mammary epithelial cells (HMECs) by expressing these
genes using recombinant adenoviruses. The control
samples received green fluorescent protein (GFP) adenovirus. The overall goal of this approach was to capture
the downstream transcriptional events specific for each
expressed GFRN gene, or the gene expression signatures,
and to use these signatures to estimate pathway activity
in cell lines and patient samples. To determine if adenovirus infection led to pathway activation for each overexpressed gene, protein levels of gene products and their
downstream targets were measured the using western
blotting (Additional file 1: Figure S1). Next, RNA-Seq
was performed on multiple replicates of HMECs overexpressing GFRN genes and GFP controls. These data
were used to generate pathway-based gene expression
signatures for each overexpressed gene using the previously published ASSIGN pathway profiling approach
(Additional file 1: Figure S2a–g) [58]. Briefly, ASSIGN
prioritized genes that best discriminated GFP control
samples from samples overexpressing GFRN genes to
generate gene expression signatures. Next, ASSIGN was
used to estimate the activation of each GFRN member
(AKT, BAD, EGFR, HER2, IGF1R, KRAS (G12V), and
RAF1) in 1119 breast cancer patient samples from
TCGA and 55 samples from the ICBP panel of breast
cancer cell lines. ASSIGN was used to measure highly
correlated GFRN pathway activity more accurately in
patient samples with signatures generated in HMECs
since ASSIGN estimates correlated pathway activities
robustly by adapting pathway signatures into specific
disease context. The robustness of each pathway signature was validated with (1) leave-one-out crossvalidation (LOOCV), (2) relevant reverse phase protein
array (RPPA) scores, (3) gene expression data for the
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overexpressed oncogenes, and (4) mutation data (Additional file 1: Methods, Figure S3, and Table S2). After
validating the GFRN signatures, gene set enrichment
analysis was performed to identify enriched signaling
patterns within each signature (“Gene set enrichment
analysis on RNA-Seq signatures” in Additional file 1:
Supplementary results; Additional file 1: Tables S3–S9;
Additional file 3).
Finally, unsupervised hierarchical clustering of the
pathway activity estimates for all GFRN signatures in
both ICBP cell lines and TCGA patient data resulted in
a dichotomous pattern (Fig. 2a, b). The HER2, IGF1R,
and AKT pathways formed a cluster, as did the
remaining BAD, EGFR, KRAS, and RAF1 pathways
(Fig. 2a, b). There was some overlap between the two
clusters, likely due to the known crosstalk and compensation that occurs between the PI3K and MAPK pathways [81]. In general, however, when one set of
pathways was high, the other set was low, which shows
that samples expressed a dominant phenotype of GFRN
activity. These results strongly suggest a pathway-level
dichotomization of the GFRN, which is represented by
two primary phenotypes: (1) activation of the HER2/
IGF1R/AKT pathways or “survival phenotype”; (2)
activation of the BAD/EGFR/KRAS/RAF1 pathways or
“growth phenotype.”
After identifying the two main dichotomous GFRN
phenotypes, these phenotypes were investigated for how
they related to classic IHC-based subtypes, intrinsic
subtypes, and additional heterogeneity present within
each phenotype (Fig. 2). To investigate if these phenotypes were independent of ER status, pathway activity
estimates were clustered for ER+ and ER− samples
separately for both ICBP and TCGA samples. The pathway activity bifurcation pattern, as represented by GFRN
phenotypes, was consistent within ER+ and ER− samples,
indicating GFRN phenotypes are partially independent of
ER status (Additional file 1: Figure S4). The variability
between histological and intrinsic subtypes can also been
seen in the heatmap sidebars for TCGA and ICBP data
(Fig. 2a–d), and in boxplots of pathway activity estimates
across clinical and intrinsic subtypes in TCGA (Additional
file 1: Figures S5 and S6). Samples classified as the survival
phenotype included samples from all histological and intrinsic subtypes (Additional file 1: Tables S10 and S11 and
Figure S7). Of the 596 TCGA tumors from the survival
phenotype, 84.74% were ER+, 72.99% were PR+, 18.12%
were HER2+, and 26.51%, 17.79%, 6.88%, and 0.34% were
of luminal A, luminal B, HER2-enriched, and basal subtypes, respectively. For the growth phenotype (n = 523),
even more heterogeneity in ER, PR, and HER2 status was
observed (ER+, 53.54%; ER−, 37.67%; PR+, 46.85%; PR−,
43.98%; HER2+, 10.33%; HER2−, 56.41%; basal, 17.78%;
Her2 enriched, 3.06%; luminal A, 13.96%; and luminal B,
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a

b

c

d

Fig. 2 Analysis of pathway activity and intrinsic subtypes in a 1119 TCGA breast cancer samples and b 55 ICBP breast cancer cell lines. HER2,
IGF1R, and AKT and BAD, EGFR, KRAS (G12V), and RAF1 pathway activities reveal two distinct clusters that were negatively associated. GFRN
characterization reveals a dichotomy in TCGA breast cancer patients, high BAD/EGFR/KRAS/RAF1 (growth phenotype; column color label shown
in aquamarine) and high HER2/IGF1R/AKT (survival phenotype; column color label shown in coral). Subtypes determined by immunohistochemistry
and intrinsic subtyping are shown on the right side row color labels. c K-means clustering of TCGA samples identifies subsets of samples within
the survival phenotype that have high HER2 activation and low HER2 activation, and subsets of samples within the growth phenotype that have
high BAD activation and low BAD activation (shown in the left side row color labels). d These clusters are also seen in ICBP
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4.02%). Hence, clinical and intrinsic subtypes varied in
each phenotype cluster, and the GFRN phenotypes provide additional information which complements existing
breast cancer clinical and intrinsic subtypes in both patient and cell line data [14, 37, 82, 83].
HER2 activity differences were also observed within
the survival phenotype, and differences in BAD activity
within the growth phenotype. To further classify samples
specifically on these differences, k-means clustering was
performed on the AKT, BAD, EGFR, and HER2 pathway
activity predictions in ICBP and TCGA. The four resulting clusters separated the survival phenotype into two
subsets of samples that had either high or low HER2
activity, and the growth phenotype into two subsets of
samples that had either high or low BAD activity. These
patterns were observed in both TCGA and ICBP datasets (Fig. 2c, d). Again, subtype plotted against these four
subgroups as presented in the sidebars reveal there is
additional heterogeneity within ER and PR status that is
captured using GFRN subgroups. Of note, a survival
analysis of the four subgroups in TCGA did not show
significant differences in survival (λ2 = 5.5, p value =
0.141; Additional file 1: Figure S8). This indicates that
these subgroups may not relate to survival directly.
Instead, these subgroups discriminate aberrant pathway
activity that may help select patient subgroups likely to
respond to specific drugs targeting those pathways.
GFRN phenotypes complement ER status and current
subtyping methods, but are more biologically focused
than current intrinsic subtypes and are useful in addition
to current IHC-based subtypes.
GFRN phenotypes and subgroups contribute to variation
found in TCGA breast cancer gene expression data

In order to determine if the GFRN phenotypes and subgroups contributed to heterogeneity in the breast cancer
data using an unbiased approach, an unsupervised PCA
was performed on 1119 breast cancer RNA-Seq samples
from TCGA. PCA is a dimension reduction method
capable of identifying uncorrelated sources of variation
within a dataset as principal components (PCs) [84, 85].
The first five PCs identified in this dataset represented
the most significant amount of variability explaining
34.3% of the total variance. The remaining components,
each accounting for less than 4% of the total variation,
were not investigated due to their minor contribution to
total variance. Of note, PC 1 was significantly associated
with average gene expression of the samples (Spearman’s
correlation −0.786, p value <0.0001), potentially reflecting technical and non-disease-related sample variation
(Additional file 1: Figure S9). However, PC 1 was included
in analyses to demonstrate its performance. To explain
variability as presented by PC values, currently used histological (ER, PR, and HER2) and intrinsic subtypes were
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compared to GFRN-based approaches. First, each classification approach was investigated if it explained variability
in each PC. When comparing PC values, significant differences were found between ER+ and ER− samples and PR+
and PR− samples for PCs 1 through 5, between HER2+
and HER2− samples for PCs 3, 4, and 5, across intrinsic
subtypes for PCs 1 through 5 (ANOVA, p value <0.0001),
between growth and survival phenotypes for PCs 2
through 5, and across four GFRN subgroups for PCs 1
through 5 (ANOVA p value <0.0001). These results indicate that significant variation underlying TCGA breast
cancer data may be contributed from multiple sources, including GFRN phenotypes, subgroups, and histological
and intrinsic subtypes.
Second, a linear modeling approach was used to model
the first five PCs with GFRN subgroups, intrinsic subtypes (PAM50), and histological (ER, PR, and HER2)
subtypes. Variance explained by each model was compared in terms of R2 values. We included 355 TCGA
tumor samples for which all of these variables were
available. ER (R2 = 0.56) and PR (R2 = 0.407) status explained a significant proportion of PC2 but explained
less than 10% of the total variability in the other PCs.
HER2 status alone explained less than 4% of the variability
for any of the PCs. Both GFRN subgroups, and intrinsic
subtypes, explained additional variability in PCs 1–5. For
all five PCs, adding the GFRN subgroups or intrinsic subtypes to clinical subtypes increased the R2 values of the
model (p value <0.01 for all models tested; Additional file
1: Figure S10 and Table S12). Specifically, adding GFRN
subtypes to a model of PCs explained an additional 10–
35% (p value <0.00001) of the variation when compared to
a model of ER status alone while PAM50 explained only
4–20% of the variation (Additional file 1: Table S12).
On a more granular level, GFRN subgroups explained
an additional 13.5% (p value <0.00001) of the variability
for PC2, which was not explained by ER status alone.
For PC3, GFRN subtypes explained an additional 35% of
the variation when compared to a model of ER status
alone (ER R2, 0.052; ER+ GFRN subtype R2, 0.398; p
value <0.00001) and intrinsic subtypes only explained an
additional 20% of the variation compared to the same
model of ER status alone (ER+ intrinsic subtype R2,
0.254; p value <0.00001). Overall, the models that contained GFRN subgroups explained a larger percentage of
the variance of PC 1, 3, and 4, and models that contained intrinsic subgroups explained a larger percentage
of the variance of PCs 2 and 5 (Additional file 1: Figure S10).
These significant R2 and p values confirm the nonredundancy of GFRN subgroups in relation to commonly
used clinical features in breast cancer. Additionally, GFRN
subgroups explain additional variance in models of
PCs 1, 3, and 4 compared to models containing intrinsic subgroups.
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Next, the variability contributed by GFRN subgroups
was investigated in relation to biological signals, or pathway activity in this case. PC values for PCs 1 through 5
were correlated with the GFRN pathway activation estimates from TCGA (Fig. 3; Additional file 1: Table S13).
Again, a striking bifurcated pattern was found in the
correlations between pathway activity and PCs in this independent variability analysis. PC 2 was positively correlated with EGFR, KRAS, RAF1, and BAD activation and
negatively correlated with HER2, IGF1R, and AKT activation. Therefore, PC 2 is demonstrating characters of
the growth phenotype. PCs 3 and 4 were positively
correlated with HER2, IGF1R, and AKT activation and
negatively correlated with EGFR, KRAS, RAF1, and
BAD activation, thus representing growth phenotype
characteristics (Fig. 3). Both PC 1 and PC5 were negatively correlated with EGFR and RAF1 activation but
positively correlated with BAD activation. Since intrinsic subtypes are derived empirically without pointing to
any specific biological phenomenon, a correlation to intrinsic subtypes could not be performed.
In summary, these novel GFRN subgroups explained a
significant amount of variability in TCGA RNA-Seq data.
The GFRN subgroups described variation beyond ER, PR,
and HER2 status in all cases, and beyond intrinsic subtypes for three out of five cases. These results suggest that
variability in breast cancer data can be further explained
in terms of the GFRN pathway activity. Therefore, GFRN
subgroups can augment current breast cancer subtyping
methods by encompassing additional heterogeneity not
captured by traditional approaches. This pathway-based
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approach may further explain specific variation in terms
of pathway activity, which may point to identifying therapeutic targets.
Breast cancer growth phenotypes bifurcate in expression
of mitochondrial apoptotic proteins

Next, differences between the survival and growth phenotypes were examined at the biological level, specifically
in terms of mitochondrial-mediated intrinsic apoptosis
mechanisms. Although cytotoxic anticancer agents induce
cell death through various mechanisms, including intrinsic
or extrinsic apoptosis, necrosis, autophagy, or mitotic catastrophe [86, 87], we focused on mitochondrial-mediated
intrinsic apoptosis mediated by BCL-2 family proteins for
the following reasons. First, BCL-2 family members, which
regulate the commitment to mitochondrial apoptosis by
balancing pro-apoptotic proteins such as BAD and BIM,
and anti-apoptotic proteins such as BCL-2 or MCL-1 [20],
have been shown to contribute to the formation, progression, and therapeutic response in breast and other cancers
[21, 88]. Second, particular GFRN signaling pathways,
such as those found in the survival and growth phenotypes, have the potential to induce apoptosis resistance by
dysregulating BCL-2 family proteins, suggesting that targeting GFRN members may lead to increased apoptosis
[23–29, 89–91]. Third, several therapeutic strategies targeting anti-apoptotic BCL-2 family members are currently
under investigation; therefore, understanding which BCL2 proteins each phenotype is expressing may provide
insight into additional treatment strategies for breast
cancer [22, 92–94].

Fig. 3 Principal component analysis across TCGA breast tumors. Correlation heatmap between principal component (PC) values from PCs 1
through 5 and ASSIGN GFRN pathway estimates from TCGA breast cancer RNA-Seq data. Red colors represent a positive correlation and blue
colors represent a negative correlation

Rahman et al. Genome Medicine (2017) 9:40

Here, Western blotting was used to investigate
whether protein expression of particular BCL-2 family
members differed in breast cancer cell lines classified as
the survival or growth phenotypes (Fig. 4). The proapoptotic protein BIM and anti-apoptotic protein MCL1 were probed across ten breast cancer cell lines of the
survival phenotype (eight ER+, two ER−), and ten cell
lines of the growth phenotype (ten ER−) (see Additional
file 2 for cell line characteristics). Higher levels of MCL1 were found in cell lines of the growth phenotype, and
higher levels of BIM were found in the survival phenotype (Fig. 4b). To determine if differences in MCL-1 and
BIM protein expression between the survival and growth
phenotypes were due to other properties, such as ER
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status, a Western blot assay was performed using cell
lines with additional heterogeneity in ER status. Although
limited by the number of ER+ cell lines of the growth
phenotype, 12 cell lines belonging to the survival phenotype (five novel ER+, three ER+ repeats from previous
assay, and four novel ER−) and seven cell lines from the
growth phenotype (one novel ER+, two novel ER−, and
four ER− repeats) were included. The protein expression
of MCL-1 and BIM were not strictly dependent on the ER
status (Additional file 1: Figure S11).
To understand if similar results could be found in patient tumors, the expression of BCL-2 family member
genes was examined, and MCL-1 gene expression was
found to be higher in the growth phenotype of TCGA

Fig. 4 Survival and growth phenotypes differ in cell survival mechanisms. a The heatmap represents scaled activation values across 20 breast
cancer cell lines used in this analysis for each GFRN pathway. b Western blot analysis for MCL-1, BIM, and B-actin control across 20 breast cancer
cell lines of either the survival phenotype or growth phenotype. c, d Boxplots between samples classified as the survival phenotype or growth
phenotype for c MCL-1 gene expression (log2 (Transcript per million)) in TCGA data, d BIM gene expression (log2 (Transcript per million)) in TCGA
and ICBP data, and protein expression (RPPA score) in TCGA data. Student t-tests were performed to determine significance
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patient tumors (n = 523) versus the survival phenotype
(n = 596, p < 0.0001) (Fig. 4c). These results were consistent with previous studies showing that EGFR signaling
can upregulate gene expression of MCL-1 [25, 89–91].
In addition to MCL-1 dysregulation, breast cancer cell
lines of the growth phenotype expressed lower levels of
the pro-apoptotic protein BIM (Fig. 4d). In support of
this assessment, lower levels of BIM (BCL2L11) gene
expression were found in ICBP breast cancer cell lines
(p = 0.0004) and TCGA tumors (p = 0.0002), and RPPA
protein expression was lower in TCGA tumors (p <
0.0001) (Fig. 4d). These results concur with literature
showing that EGFR signaling through ERK activation
can lead to repression of BIM [27–29]. Also, the cooccurrence of high MCL-1 levels and low BIM levels in
the growth phenotype are likely due to MCL-1’s known
ability to bind and neutralize BIM, which leads to prevention of apoptosis death effector activation [21, 95].
In summary, these results show an interesting mitochondrial apoptotic pathway induction that is dependent on
GFRN activity. Specifically, breast tumors classified as
the growth phenotype may overexpress MCL-1 and
inhibit BIM expression to achieve cell survival. These
findings illustrate that breast cancer phenotypes, defined
by activation of specific growth factor receptor pathways, express different apoptotic proteins and may resist
apoptosis differently.

these phenotypes were investigated in relation to drug
response in breast cancer cell lines. Pathway activation
estimates were correlated with drug response data for
90 drugs from the ICBP breast cancer cell line panel.
Importantly, a consistent bifurcation pattern was observed
for drug response in the cell line data that matched the
observed pathway-level bifurcation. Specifically, cancer
cells classified as expressing the survival phenotype were
sensitive to therapies that target AKT, PI3K, HER2, and
mTOR (Fig. 5a). Additionally, these cell lines were more
resistant to chemotherapies and targeted therapies that
block EGFR and MEK. In contrast, cancer cells expressing
the growth phenotype were sensitive to chemotherapeutics such as docetaxel, paclitaxel, and cisplatin. These cell
lines were also sensitive to EGFR- and MEK-targeted
therapies, but more resistant to AKT, PI3K, HER2, and
mTOR inhibitors (Fig. 5a).
This dichotomy in drug response of the survival and
growth phenotypes was further tested in an independent
drug response assay. Eight drugs on a panel of 23 breast
cancer cell lines were tested (see Additional file 2: Sheet 1
for cell lines), and cell viability was tested upon drug
treatment by measuring ATP levels. Drugs included were
obatoclax (BCL-2, BCL-XL, BCL-W, BAK inhibitor),
UMI-77 (selective MCL-1 inhibitor), erlotinib (EGFR
inhibitor), doxorubicin (topoisomerase II inhibitor), trametinib (MEK inhibitor), neratinib (pan-HER tyrosine
kinase inhibitor), Sigma-Aldrich AKT1/2 inhibitor (dual
AKT1/2 inhibitor), and bafilomycin (apoptosis inducer
that inhibits PI3K/AKT signaling and autophagy inhibitor)
at different doses (Additional file 2: Sheet 2). Again, a

GFRNs predict drug response in breast cancer

Since there was a clear dichotomy in the GFRN signaling
mechanisms between the survival and growth phenotypes,

a

b

Fig. 5 Growth factor receptor network phenotypes reflect dichotomous drug response in breast cancer cell lines. Colors correspond to scaled
Spearman correlations between specific pathway activation estimates generated with ASSIGN and drug sensitivity (−logGI50) across a 55 breast
cancer cell lines from the ICBP panel and b 23 breast cancer cell lines in an independent drug assay. Red represents positive correlation and blue
represents negative correlation. Pathways cluster across the x-axis as AKT growth phenotype (coral color) and EGFR growth phenotype (green).
Drug classes are represented along the y-axis: pink, HER2/AKT/PI3K/mTOR-targeted therapies; yellow, chemotherapies/BCL-2 targeting therapies;
and blue, EGFR/MEK-targeted therapies
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discrete pattern was observed between the survival and
growth phenotypes that translated to a bifurcated drug response pattern (Fig. 5b). Responses to the chemotherapy
(doxorubicin) and the EGFR pathway inhibitor (erlotinib)
were high for the growth phenotype. In contrast, cancer
cell lines classified as the survival phenotype responded
well to drugs targeting components of the PI3K pathway, such as Sigma-Aldrich AKT1/2 inhibitor, neratinib, and bafilomycin.
In addition to the bifurcation of GFRN and drug response, breast tumor cells of the growth phenotype
showed a higher response to the specific MCL-1 inhibitor
UMI-77 (Fig. 5b). This is consistent with the findings that
samples within the growth phenotype have higher MCL-1
expression than the survival phenotype. Response to obatoclax could not be clearly distinguished based on these
phenotypes, likely due to its nonspecific binding to prosurvival proteins, including BCL-2, BCL-XL, and MCL-1
[96]. Overall, the GFRN phenotype-based drug response
predictions were validated in this independent drug
response assay. Additionally, drug sensitivity of emerging
therapies such as UMI-77, neratinib, and bafilomycin
showed differences between the two phenotypes, further
highlighting the close relationship between GFRN signaling activity and response to therapies directed at pathways
in this network.
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When GFRN phenotype subgroups were considered,
several drugs in the ICBP drug response assay showed
significantly different drug response profiles in the subgroups found in each GFRN phenotypic arm. For example, the PI3K and mTOR inhibitor GSK1059615 and
HER2/EGFR-targeting drug lapatinib were more effective
in cell lines within the survival phenotype showing higher
HER2 activity (p = 0.009 and p < 0.000001, respectively;
Fig. 6a, b). Additionally, ICBP cell lines expressing the
growth phenotype responded better to EGFR-targeting
drugs AG1478 and gefitinib in the EGFR/BAD low cluster
compared to the EGFR/BAD high cluster (p = 0.001 and
p = 0.001, respectively; Fig. 6c, d).
To determine if this bifurcation pattern was independent of clinical and intrinsic subtyping approaches,
the correlations between pathway activation and drug
response for ER+ and ER− and HER+ and HER− ICBP
cell lines were clustered separately. Again, cell lines
with high AKT/IGF1R/HER activity, i.e., the survival
phenotype, were more sensitive to HER2/AKT/PI3Ktargeted drugs even within ER− and HER− cell lines
(Additional file 1: Figure S12). In ER+ and HER+ cell
lines, many PI3K/AKT/HER2-targeting drugs are more
effective in the survival phenotype, as expected. However, there was additional drug response heterogeneity
within ER+ samples that is associated with variations in

a

b

c

d

Fig. 6 Differential drug response identified in GFRN phenotype heterogeneity. Boxplots of –log (EC50) drug response data from four drugs in
the drug assay that show a differential drug response within growth factor phenotypes. a GSK1059615, a PI3K and mTOR inhibitor, caused an
increase in response in samples within the survival phenotype classified as having high HER2 activity. b Lapatinib, a HER2 inhibitor, stimulated
a stronger response in samples within the survival phenotype with high HER2 activity. c AG1478 and d gefitinib, EGFR inhibitors, caused an
increased response in samples within the growth phenotype classified as having low BAD activity
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BAD and HER2 pathway activity. These subgroups are
thus helpful to further classify samples for better drug
response prediction. To assess drug response across
ER, PR, and HER2 status and intrinsic subtypes, it was
found that out of 90 drugs studied in ICBP only 13
(14.4%), 12 (13.3%), and 19 (21.1%) showed significant
differences in drug response based on ER, PR, and
HER2 status, respectively, but growth/survival phenotypes were significant for 27 (49%) (Additional file 1:
Table S14). As further evidence, while HER2 positive
status is a biomarker for effective HER2-targeted therapy, drug sensitivity does not solely depend on HER2
status. For example, while HER2 status performs much
better in differentiating lapatinib’s response than ER
and PR status (p < 0.0001), some HER2− cell lines, such as
HCC70 and 184A1, may respond to lapatinib (Additional
file 1: Figure S13a–c). The subgroup analysis showed
the survival/HER2 high subgroup to be more sensitive
to lapatinib than any other subgroup (Fig. 6b). In contrast, intrinsic subgroup analysis showed, in general,
that the luminal subtype was more sensitive, but significant variability in lapatinib sensitivity exists within the
luminal subtype (Additional file 1: Figure S13d). Other
detailed examples describing comparisons between the
GFRN phenotypes and other methods are included in
Fig. 6. In conclusion, the GFRN phenotypes provide
additional information to current approaches; GFRN
phenotypes and subgroups could be used to further stratify
samples and may help select more appropriate candidates
for effective drug response.

Discussion
Targeted therapies directed against the key members of
the growth factor receptor network (GFRN), such as
EGFR, PI3K, AKT, and mTOR inhibitors, are currently
in preclinical development, clinical trials, or approved
for use in breast cancer [16]. However, predicting patients’ responses to therapies is challenging due to difficulties in measuring complex signaling events in tumors.
Here, this issue was addressed by investigating global
GFRN activity in breast cancer using these novel signatures. Two discrete patterns of GFRN pathway activity,
or phenotypes, were found (Fig. 7). The survival phenotype was characterized by the activation of the HER2,
AKT, and IGF1R pathways, and the growth phenotype
by the activation of the EGFR, KRAS, RAF1, and BAD
pathways. Additional subgroups were also found within
the survival and growth phenotypes, including HER2
high and low activity groups within the survival phenotype and BAD high and low activity groups within the
growth phenotype. Although these discrete phenotypes
were named the survival and growth phenotypes for
simplicity, GFRN pathways comprising both groups can
contribute to growth and survival. To the best of our
knowledge, this is the first study to characterize GFRN
activity using signature-based representations of activity
across multiple pathways.
These discrete subgroups displayed differences in response to targeted therapies and chemotherapies in breast
cancer cell lines. For example, conventional chemotherapies such as docetaxel, paclitaxel, and doxorubicin were
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Fig. 7 Summary of the survival and growth phenotypes in breast cancer. The survival phenotype is characterized by high HER2, IGF1R, and AKT
pathway activation, high expression of pro-apoptotic BIM, low expression of anti-apoptotic MCL-1, and response to HER2, AKT, PI3K, and mTOR
inhibitors. The growth phenotype is characterized by high EGFR, KRAS, and RAF1 activation, high expression of MCL-1, low expression of BIM, and
response to EGFR/MEK-targeted therapies and chemotherapies
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more effective for the growth phenotype than the survival
phenotype. Sensitivity to PI3K, HER2, AKT, and mTOR
inhibitors and resistance to conventional chemotherapies
were also found in the survival phenotype. Among the
subgroups, the survival phenotype/high HER2 subgroup
was hypersensitive to lapatinib, a HER2 and EGFR dual
inhibitor. Similarly, the survival phenotype/high HER2
subgroup was more sensitive to GSK1059615, a PI3K/
mTOR inhibitor than the survival phenotype/low HER2
subgroup. Cell lines of the growth phenotype responded
better to EGFR and MEK inhibitors and to conventional
chemotherapies. The growth phenotype/low BAD subtype
was more sensitive to both AG1478 and gefitinib (EGFR
inhibitors) than the growth phenotype/high BAD subtype.
Overall, the GFRN pathway-based phenotyping contributed to information related to drug response.
Analysis of these novel phenotypes in breast cancer
cell lines and tumors also revealed interesting differences
in intrinsic apoptosis. For example, breast cancer cell
lines and tumors of the growth phenotype had higher
levels of the anti-apoptotic protein MCL-1 and lower
levels of the critical pro-apoptotic protein BIM. These
results are consistent with the notion that the MAPK
pathway can activate MCL-1 expression and that activation of ERK1/2 and the MAPK pathway can repress BIM
[25, 27–29]. An independent drug assay also showed
that the growth phenotypic cell lines responded better to
a MCL-1 inhibitor (UMI-77). These results suggest that
the patients with growth phenotypic expression may
benefit from treatments that increase BIM, i.e., MCL-1
inhibitors, in combination with chemotherapies, EGFR
inhibitors, or other inhibitors of the MAPK pathway
[97, 98]. Therefore, targeting GFRN members may be an
effective therapeutic strategy for inhibiting GFRN pathways and increasing apoptosis [22]. These results highlight
that mapping phenotypes, such as growth networks in
breast tumors, can be exploited to guide the use of targeted therapies. This study was limited to how GFRN
activity related to drug response and cellular intrinsic
apoptosis, but it is understood that this is not the sole
mechanism by which cancer cells die, and other cell death
mechanisms, such as necrosis, autophagy, and mitotic catastrophe, should also be considered. In addition, as the
use of cell lines is limited, a larger-scale analysis of
apoptotic pathways dysregulation in patient tumor cells of all
subtypes will be informative in further detailing how these
pathways signal in cancer. These phenotypes many
correlate with other subtyping properties, and may also
be confounded by properties of intrinsic subtyping.
Importantly, these newly discovered breast cancer
survival and growth phenotypes are biologically relevant
and offer a direct method for probing and targeting the
GFRN in breast tumors. In addition, these phenotypes
complement widely used clinical and intrinsic subtypes,
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and stratification of cancers by these phenotypes leads
to enhanced drug response predictions compared to
classifying cancers by clinical subtyping approaches. This
is most likely because oncogenic pathway activation was
measured more comprehensively than relying on single
protein measurements. In addition, this approach considers crosstalk between members of the GFRN and correlates with biological processes such as cell survival.
This pathway-based approach for identifying phenotypes
allows for exploration of additional heterogeneity occurring within the identified phenotypes, which can further
improve the ability to stratify breast cancers by pathway
activity, which then can be used to predict drug response. Although this method has added to current approaches for predicting drug response in breast cancer,
most experiments were performed in breast cancer cell
lines with particular classes of drugs; additional drug
testing should be performed in breast cancer patient
cells in order to confirm these phenotypes.
In summary, a novel genomic pathway-based approach
of characterizing the interactive GFRN activation in
breast cancer was used to discover two discrete GFRN
phenotypes with significant differences in cell survival
mechanisms and drug response in breast cancer. These
phenotypes captured the distinct bifurcation pattern seen
in gene expression, the GFRN pathway activity, mitochondrial apoptotic network protein expression, and drug response (Fig. 7). While ER, PR, HER2 status and, more
recently, intrinsic subtype are used to guide breast cancer
treatment, these subtyping or classifying approaches may
not describe signaling pathway dysregulation in tumor
cells. Pathway activity data provide additional information
about tumor cells that can be leveraged to predict drug response. Characterizing individual tumors into these phenotypes can help determine which patients will benefit
from a treatment and select the appropriate subpopulations for clinical trials. Importantly, these seven pathways
did not capture all the heterogeneity of the samples and
inclusion of other pathways may have additional benefits.
Although feasible, additional investigation is needed
before these phenotypes can be used in clinical trials
for patient selection, including the testing of these phenotypes in patient primary tumor cells.

Conclusions
A discriminating bifurcation pattern of key GFRN pathways was identified in breast tumors that expands beyond
histological and clinical subtypes. These phenotypes
correlated with unique apoptotic and drug response
mechanisms. The ability to measure signaling events more
accurately in patient tumors advances understanding of
the biological basis of cancer. These results may lead to
more effective and individualized treatment selection in
patients with breast cancer.
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